戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 g or metabolic studies, and development of a bioartificial liver.
2 ery, and therapeutic applications, such as a bioartificial liver.
3 as drug screening, toxicological studies, or bioartificial livers are reliant on hepatocyte functiona
4 ause of the potential to use these cells for bioartificial livers, as a vehicle for gene transfer, an
5 art of an extracorporeal system, such as the bioartificial liver assist device, or an implantable tis
6           Over the years, the development of bioartificial liver-assist devices has aimed at replacin
7                    We have developed a novel bioartificial liver (BAL) composed of porcine hepatocyte
8  from lymphocytes of patients treated with a bioartificial liver (BAL) containing pig hepatocytes and
9   The purpose of this study was to develop a bioartificial liver (BAL) to treat patients with severe
10 s an extracorporeal porcine hepatocyte-based bioartificial liver (BAL).
11 dy source of metabolic function for use in a bioartificial liver (BAL).
12  to pig hepatocytes after treatment with the bioartificial liver (BAL).
13 low fiber membranes, such as those used in a bioartificial liver, block the transfer of PERV.
14                     This is a key advance in bioartificial liver development.
15 corporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic fa
16  limitations of novel technologies including bioartificial liver devices and auxiliary liver transpla
17              This has prompted the design of bioartificial liver devices to "bridge" patients until t
18 l hepatology and cell-based therapies (e.g., bioartificial liver devices).
19 ion of cryopreserved isolated hepatocytes in bioartificial liver devices.
20  therapies for liver disorders or for use in bioartificial liver devices.
21 ned, implemented and tested a clinical-scale BioArtificial Liver machine containing a biomass derived
22                                            A BioArtificial Liver machine could temporarily replace th
23 heroids appear suitable for application in a bioartificial liver or as an in vitro liver tissue const
24                               Extracorporeal bioartificial liver support devices remain an exciting b
25                     Advances in the field of bioartificial liver support have led to an increasing de
26 ck, neither of which is likely to respond to bioartificial liver support or treatment with convention
27 olved in a phase I/II clinical trial using a bioartificial liver support system (BLSS), we proceeded
28                               Artificial and bioartificial liver support systems have thus far not de
29 atocyte cocultures, typically extracorporeal bioartificial liver support systems, are reviewed in the
30 ttempted by various approaches, for example, bioartificial liver support, extracorporeal pig liver pe
31 ll research may allow provision of cells for bioartificial liver support.
32 particularly for cell therapeutics including bioartificial liver systems (BALs).
33 he risk of viral exposure to patients during bioartificial liver therapy.
34                                          The BioArtificial liver (UCLBAL) improved important prognost